Launchpad Therapeutics is focused on developing a portfolio of early mutant selective antibody programs enabled by AI-driven and structure supported drug design. Launchpad's mission is to deliver novel monoclonal antibody (mAb) design from sequence, to structure, to function. Made up of a team of experienced drug hunters, computational scientists and simulation experts, Launchpad is positioned to unlock the value of early antibody projects spun out of Black Diamond Therapeutics' MAP (Mutation-Allostery-Pharmacology) Drug Discovery Engine. Launchpad's platform is able to uniquely deliver cancer cell specific antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/12/22 | $30,000,000 | Series A |
Black Diamond Therapeutics New Enterprise Associates Versant Ventures | undisclosed |
